Cargando…
Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
PURPOSE: Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 ((90)Y) and lutetium-177 ((177)Lu) are two of the most promising beta-particle emitting radionuclides...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364776/ https://www.ncbi.nlm.nih.gov/pubmed/25785845 http://dx.doi.org/10.1371/journal.pone.0120561 |
_version_ | 1782362126729347072 |
---|---|
author | Frost, Sofia H. L. Frayo, Shani L. Miller, Brian W. Orozco, Johnnie J. Booth, Garrett C. Hylarides, Mark D. Lin, Yukang Green, Damian J. Gopal, Ajay K. Pagel, John M. Bäck, Tom A. Fisher, Darrell R. Press, Oliver W. |
author_facet | Frost, Sofia H. L. Frayo, Shani L. Miller, Brian W. Orozco, Johnnie J. Booth, Garrett C. Hylarides, Mark D. Lin, Yukang Green, Damian J. Gopal, Ajay K. Pagel, John M. Bäck, Tom A. Fisher, Darrell R. Press, Oliver W. |
author_sort | Frost, Sofia H. L. |
collection | PubMed |
description | PURPOSE: Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 ((90)Y) and lutetium-177 ((177)Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas (90)Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with (177)Lu. We therefore compared the therapeutic potential of targeting either (90)Y or (177)Lu to human B-cell lymphoma xenografts in mice. METHODS: Parallel experiments evaluating the biodistribution, imaging, dosimetry, therapeutic efficacy, and toxicity were performed in female athymic nude mice bearing either Ramos (Burkitt lymphoma) or Granta (mantle cell lymphoma) xenografts, utilizing an anti-CD20 antibody-streptavidin conjugate (1F5-SA) and an (90)Y- or (177)Lu-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin second step reagent. RESULTS: The two radionuclides displayed comparable biodistributions in tumors and normal organs; however, the absorbed radiation dose delivered to tumor was more than twice as high for (90)Y (1.3 Gy/MBq) as for (177)Lu (0.6 Gy/MBq). More importantly, therapy with (90)Y-DOTA-biotin was dramatically more effective than with (177)Lu-DOTA-biotin, with 100% of Ramos xenograft-bearing mice cured with 37 MBq (90)Y, whereas 0% were cured using identical amounts of (177)Lu-DOTA-biotin. Similar results were observed in mice bearing Granta xenografts, with 80% of the mice cured with (90)Y-PRIT and 0% cured with (177)Lu-PRIT. Toxicities were comparable with both isotopes. CONCLUSION: (90)Y was therapeutically superior to (177)Lu for streptavidin-biotin PRIT approaches in these human lymphoma xenograft models. |
format | Online Article Text |
id | pubmed-4364776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43647762015-03-23 Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models Frost, Sofia H. L. Frayo, Shani L. Miller, Brian W. Orozco, Johnnie J. Booth, Garrett C. Hylarides, Mark D. Lin, Yukang Green, Damian J. Gopal, Ajay K. Pagel, John M. Bäck, Tom A. Fisher, Darrell R. Press, Oliver W. PLoS One Research Article PURPOSE: Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 ((90)Y) and lutetium-177 ((177)Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas (90)Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with (177)Lu. We therefore compared the therapeutic potential of targeting either (90)Y or (177)Lu to human B-cell lymphoma xenografts in mice. METHODS: Parallel experiments evaluating the biodistribution, imaging, dosimetry, therapeutic efficacy, and toxicity were performed in female athymic nude mice bearing either Ramos (Burkitt lymphoma) or Granta (mantle cell lymphoma) xenografts, utilizing an anti-CD20 antibody-streptavidin conjugate (1F5-SA) and an (90)Y- or (177)Lu-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin second step reagent. RESULTS: The two radionuclides displayed comparable biodistributions in tumors and normal organs; however, the absorbed radiation dose delivered to tumor was more than twice as high for (90)Y (1.3 Gy/MBq) as for (177)Lu (0.6 Gy/MBq). More importantly, therapy with (90)Y-DOTA-biotin was dramatically more effective than with (177)Lu-DOTA-biotin, with 100% of Ramos xenograft-bearing mice cured with 37 MBq (90)Y, whereas 0% were cured using identical amounts of (177)Lu-DOTA-biotin. Similar results were observed in mice bearing Granta xenografts, with 80% of the mice cured with (90)Y-PRIT and 0% cured with (177)Lu-PRIT. Toxicities were comparable with both isotopes. CONCLUSION: (90)Y was therapeutically superior to (177)Lu for streptavidin-biotin PRIT approaches in these human lymphoma xenograft models. Public Library of Science 2015-03-18 /pmc/articles/PMC4364776/ /pubmed/25785845 http://dx.doi.org/10.1371/journal.pone.0120561 Text en © 2015 Frost et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Frost, Sofia H. L. Frayo, Shani L. Miller, Brian W. Orozco, Johnnie J. Booth, Garrett C. Hylarides, Mark D. Lin, Yukang Green, Damian J. Gopal, Ajay K. Pagel, John M. Bäck, Tom A. Fisher, Darrell R. Press, Oliver W. Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title | Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title_full | Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title_fullStr | Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title_full_unstemmed | Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title_short | Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models |
title_sort | comparative efficacy of (177)lu and (90)y for anti-cd20 pretargeted radioimmunotherapy in murine lymphoma xenograft models |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364776/ https://www.ncbi.nlm.nih.gov/pubmed/25785845 http://dx.doi.org/10.1371/journal.pone.0120561 |
work_keys_str_mv | AT frostsofiahl comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT frayoshanil comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT millerbrianw comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT orozcojohnniej comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT boothgarrettc comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT hylaridesmarkd comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT linyukang comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT greendamianj comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT gopalajayk comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT pageljohnm comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT backtoma comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT fisherdarrellr comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels AT pressoliverw comparativeefficacyof177luand90yforanticd20pretargetedradioimmunotherapyinmurinelymphomaxenograftmodels |